Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | CTRC | Q99895 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16021756 | 0.90 | DPP4 (0.55) | DPP4EGFRRETKDRCTRC | |
| SCHEMBL21291339 | 0.87 | DPP4 (0.49) | DPP4EGFRRETKDRCTRC | |
| SCHEMBL14838413 | 0.78 | DPP4 (0.41) | DPP4EGFRRETKDRCTRC | |
| SCHEMBL16021800 | 0.77 | DPP4 (0.39) | DPP4EGFRRETKDRCTRC | |
| SCHEMBL14838338 | 0.75 | DPP4 (0.36) | DPP4EGFRRETKDRCTRC | |
| SCHEMBL915494 | 0.75 | MEN1 (0.34) | DPP4 | |
| SCHEMBL21291343 | 0.73 | DPP4 (0.33) | DPP4EGFRRETKDRCTRC | |
| SCHEMBL14838370 | 0.73 | DPP4 (0.32) | DPP4 | |
| SCHEMBL14838249 | 0.72 | HDAC1 (0.31) | DPP4 | |
| SCHEMBL21291337 | 0.72 | PGR (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124524-B2 | Diarylethene compounds and uses thereof | SOLUTIA CANADA INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20190256526-A1 | DIARYLETHENE COMPOUNDS AND USES THEREOF | SWITCH MATERIALS, INC. (CA) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256526-A1 | DIARYLETHENE COMPOUNDS AND USES THEREOF | KCNH2, KCNH3, SCN2B | DPP4 4383/4885EGFR 1177/4885RET 2230/4885 |
| US-11124524-B2 | Diarylethene compounds and uses thereof | KCNH2, KCNH3, SCN2B | DPP4 4383/4885EGFR 1177/4885RET 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.